Background: Patients with non-resectable colorectal metastases are currently treated with chemotherapy. However, liver transplantation can increase the 5-year survival rate from 9 to 56 per cent if the cancer is confined to the liver. The aim of this study was to estimate the cost-effectiveness of liver transplantation for colorectal liver metastases.
Introduction
Approximately 27 per cent of patients with colorectal cancer are diagnosed with liver metastases within 3 years of diagnosis 1 . If the liver metastases are not resectable no curative treatment is available and patients receive chemotherapy or best supportive care 1, 2 . The expected 5-year survival rate for patients with non-resectable colorectal liver metastases (CLM) receiving chemotherapy is about 10 per cent 3, 4 .
In the early days of liver transplantation (LTx), metastatic colorectal cancer was a contraindication to transplantation owing to the poor results achieved. Before 1995, 1-and 5-year survival rates were 76 and 12 per cent respectively 5 -9 . In recent years, overall survival after LTx has improved, immunosuppressant drugs with antiproliferative properties have been developed, and better diagnostic imaging is available 5, 6 . Because of this, the SECA-I trial re-examined LTx as a treatment option for patients with metastatic colorectal cancer 5, 10 . In SECA-I 11 , the 5-year survival rate after LTx was 56 per cent, compared with 9 per cent in a cohort of similar patients receiving chemotherapy alone. Thus, the survival rate was above the 50 per cent threshold often used to define LTx as worthwhile, and comparable with the survival rate of patients currently undergoing LTx for other indications 12, 13 .
In Western countries, healthcare budgets are increasingly being used for new oncological treatments targeting patients with cancer at the end of life, where the effects are marginal and costs are high both for society and for patients (in terms of toxicity) 14 -16 . In countries where the time on waiting lists is short and waiting list mortality is low, decision-makers should consider whether LTx is an alternative treatment for patients with non-resectable CLM. As part of that process, they need information on the cost-effectiveness of LTx 17 . The objective of this study was to estimate the long-term expected life-years and quality-adjusted life-years (QALYs), cost consequences and cost-effectiveness of introducing LTx to patients with CLM compared with chemotherapy alone (cytotoxic drugs/antibodies).
Methods
The study was approved by the Regional Committee for Medical and Health Research Ethics in Norway and by the Institutional Review Board at Oslo University Hospital.
Cost-effectiveness analyses
The goal of a cost-effectiveness analysis is to inform decision-makers on the cost per additional effect of introducing a new treatment, compared with relevant treatment options, defined by the incremental cost-effectiveness ratio (ICER):
ICER=
Cost of transplantation -cost of chemotherapy Effect of transplantation -effect of chemotherapy
If the ICER falls below the willingness-to-pay threshold (WTP), the intervention is considered cost-effective and should, if other prioritization criteria are met, be implemented 18 -20 . In Norway, the three prioritizing criteria are: effect of the intervention, resource use and severity of the disease 20 .
Markov model
A Markov model was used to estimate health effects and costs ( Fig. 1) 18, 19 . The model includes the health states disease-free, recurrence, palliative and death, indicated by circles in Fig. 1 . A model runs in cycles. The duration of each cycle was defined as 3 months. After a cycle, patients can move between the health states, indicated by arrows in Fig. 1 . In the analyses, one cohort of patients received standard treatment (chemotherapy alone) and another received LTx. Patients entered the model in palliative (if allocated to chemotherapy alone) or disease-free (if allocated to LTx). QALYs and costs were assigned to all health states, so life-years, QALYs and costs accumulated depended on the number of patients who stayed in the different health states per cycle when the model was run.
Tunnel states were applied to relax the Markovian assumption, which states that the model is 'memoryless' (the time spent in a health state does not affect costs/transition probabilities). A patient can stay in a tunnel state for only one cycle, before either moving to the next tunnel state, or moving to another health state. By applying different costs/transition probabilities to the different tunnel states, time dependency was introduced in the model 19 . Disease-free included one tunnel state, to reflect the initial high costs of LTx. In both recurrence and palliative, 40 tunnel states were included to allow for time-dependent transition probabilities over 10 years (after which survival analyses showed that transition probabilities stabilized). The tunnel states in recurrence also enabled differentiation between the number and types of resection surgery that patients underwent in the first year after recurrence compared with the subsequent years after recurrence, whereas the tunnel states in palliative enabled differentiation between the types of chemotherapy regimen that patients received, which changed over time.
Model input

Data sources
The model was populated using data from the SECA-I trial 11 and the NORDIC-VII trial 21 . In SECA-I 11 , 23 patients with non-resectable liver-only CLM received liver transplants between 2006 and 2012. A multidisciplinary team evaluated non-resectability. Two LTx cohorts were simulated through the model: LTx (all), based on the original SECA-I population of 23 patients; and LTx (selected), based on a subgroup of 16 patients from the SECA-I population. Selection for LTx (selected) was based on risk factors associated with poor survival: tumour diameter larger than 5⋅5 cm, time since primary cancer surgery less than 2 years, carcinoembryonic antigen levels above 80 μg/l, and progressive disease after chemotherapy at the time of LTx 10 . Patients with three or fewer risk factors were included in LTx (selected).
In NORDIC-VII 21 , 566 patients were randomized to Nordic FLOX (oxaliplatin, 5-fluorouracil and leucovorin), FLOX plus cetuximab, or FLOX intermittently plus cetuximab continuously. There were no significant differences in progression-free or overall survival between the groups. The same cohort of patients from the NORDIC-VII trial as Dueland and colleagues used in their comparison 11 was used in the present study. There, all patients from the NORDIC-VII trial were combined and thereafter selected based on the criteria used in the SECA-I trial: non-resectable liver-only metastases, non-mutated BRAF and age less than 66 years. Patients who underwent liver resection after inclusion were excluded. Two chemotherapy cohorts were simulated through the model: chemotherapy (all), the selected cohort of 47 patients from the NORDIC-VII trial; and chemotherapy (selected), the 21 patients who survived longest among the selected cohort. The proportion of patients simulated to start second-line chemotherapy was 57 per cent, the same as the proportion whose disease had progressed on first-line chemotherapy in the SECA-I trial 11 .
Transition probabilities
For all patients who underwent LTx, the date of transplantation, documented date of recurrence, start date of chemotherapy and date of death were identified from patient records (SECA-I trial) with a 5-year cut-off. For all patients who had chemotherapy, the start time of chemotherapy and time of death were identified from published Kaplan-Meier curves for overall survival 11 , and extracted using WebPlotDigitizer 22 . Parametric survival analyses (stratified by the 4 cohorts) were applied to estimate transition probabilities between the health states. Parametric survival analyses enable transition probabilities to differ depending on time. The Akaike information criterion and Bayesian information criterion were used to choose the best model among several parametric specifications of the survival function: exponential, Weibull, log-normal, log-logistic, Gompertz or gamma 23 . Although the postoperative mortality rate was zero in the SECA-I trial, a 2 per cent probability of postoperative death after LTx was assumed based on published data 12, 24 . For disease-free and recurrence states, the probability of death was assumed to be similar to the background mortality in the Norwegian general population 25 . The transition probabilities used in the model are shown in Table S1 (supporting information).
Costs
Direct healthcare costs were estimated, including the cost of transplantation, organ harvesting, retransplantation, postoperative complications (readmissions within 3 months after transplantation), routine follow-up by hospital and general practitioners (GPs), immunosuppressive drugs, tumour-targeting treatments patients received in hospital for recurrent cancer, chemotherapy (chemotherapy drugs, administration of the drugs and hospital admission owing to side-effects of chemotherapy), and best supportive care. Resource use was quantified through patient records (SECA-I trial), LTx guidelines 26 , using a Markov model of the treatment path of patients with colorectal cancer reported by Joranger and colleagues 27 , and based on expert opinions. It was assumed that costs were equal for all patients once they entered the palliative state, except for immunosuppressive drugs that the patients who had undergone LTx continued to take while receiving chemotherapy. The cost of best supportive care was assigned to all patients in the 3-month cycle before death, except for patients who died directly after LTx. All hospital treatments, GP consultations and medication were valued using the Norwegian Diagnosis Related Groups (DRGs) 28 , the Norwegian GP tariffs 29 and estimates from the Norwegian Medicines Agency 30 . Costs were estimated on a present value basis, using euro 2016 (€1 = NOK 9⋅2899, average exchange rate in 2016). Further details of the cost estimates can be found in Appendix S1 and Table S2 (supporting information).
Effects
Effects were estimated in terms of life-years and QALYs. QALYs combine time with health-related quality of life (HRQoL). HRQoL is a measure anchored in dead [0] and perfect health [1] . A literature search was performed to identify papers reporting HRQoL after LTx and for patients with CLM; based on the findings, HRQoL values were assigned to the different health states (Table S2 , supporting information) 31, 32 .
Analyses
A cohort of 1000 patients aged 55 years were simulated through the model. Costs and effects were discounted at a rate of 4 per cent 33 . The model's time horizon was 25 years, which was assumed equivalent to a lifetime perspective.
Outcomes of the model include life-years, QALYs, direct healthcare costs and ICERs. One-way sensitivity analyses and probabilistic sensitivity analyses (PSAs) were performed. In the PSAs, all input parameters were drawn randomly from predefined distributions (Tables S1 and S2, supporting information) in 1000 iterations 34 . Data from the PSA were used to estimate the probability that LTx and chemotherapy alone were cost-effective for increasing WTP thresholds, presented in cost-effectiveness acceptability curves 35 . Cost-effectiveness results were therefore displayed using varying WTP thresholds, with specific reference to €70 500 based on Norwegian guidelines 33 . The individual expected value of perfect information (EVPI) was also estimated from the PSA, which quantifies the monetary loss associated with adopting the wrong treatment strategy 36, 37 .
As results were extrapolated beyond 5 years using parametric survival analyses, a range of scenario analyses were performed to see how optimistic extrapolation (predicting slow progression through the model) and pessimistic extrapolation (predicting fast progression through the model) in the LTx cohorts would alter the results (Appendix S2 and Table S3 supporting information). The face validity, internal validity and external validity of the model were assessed (Appendix S3, supporting information).
The analyses were carried out using Stata ® version 14 (StataCorp, College Station, Texas, USA) and Excel ® (Microsoft, Redmond, Washington, USA).
Results
Effect
Patients in LTx (all) had an incremental effect of 3⋅12 life-years (2⋅47 QALYs) compared with those in Table 1 Expected life-years, quality-adjusted life-years, costs and cost-effectiveness of liver transplantation compared with chemotherapy Values are shown for the base case, except *minimum and maximum values achieved for the base case and the following six scenario analyses: the optimistic 1 scenario uses the most optimistic survival function from recurrence to chemotherapy (slow progression from recurrence to chemotherapy); optimistic 2 uses the most optimistic survival function from recurrence to chemotherapy and the most optimistic survival function from chemotherapy to death (slow progression from recurrence to chemotherapy and from chemotherapy to death); pessimistic 1 uses the most pessimistic survival function from recurrence to chemotherapy (fast progression from recurrence to chemotherapy); pessimistic 2 uses the most pessimistic survival function from recurrence to chemotherapy and the most pessimistic survival function from chemotherapy to death (fast progression from recurrence to chemotherapy and from chemotherapy to death); in the survivors scenario, it is assumed that patients who are still in the recurrence health state after 10 years have similar background mortality to the general population; in the optimistic survivors scenario, it is assumed that the most optimistic survival function from recurrence to chemotherapy (slow progression from recurrence to chemotherapy) applies and that patients who are still in recurrence after 10 years have similar background mortality to the general population. QALY, quality-adjusted life-year; CE (probability), probability that liver transplantation is cost-effective.
chemotherapy (all). Patients in LTx (selected) had an incremental effect of 4⋅23 life-years (3⋅41 QALYs) compared with those in chemotherapy (selected) ( Table 1) .
Costs
Lifetime costs were €240 878 for LTx (all), €31 735 for chemotherapy (all), €273 337 for LTx (selected) and €43 055 for chemotherapy (selected). The LTx procedure costs, including retransplantation and treatment for complications, accounted for 52 and 44 per cent of the total costs for LTx (all) and LTx (selected) respectively. In the LTx cohorts, the majority of costs occurred during the first year, and decreased over time (Figs 2 and 3) .
Cost-effectiveness
The ICER was €67 140 per life-year (€84 667 per QALY) gained in the non-selected cohorts and €54 467 per life-year (€67 509 per QALY) gained in the selected 5 Cost-effectiveness acceptability curves and expected value of perfect information (EVPI) for unselected and selected cohorts, with quality-adjusted life-years as the effect measure. LTx, liver transplantation cohorts. The likelihood that LTx was cost-effective was higher than 0⋅50 for WTP thresholds above €66 000 (LTx all) and €52 000 (LTx selected) when life-year was used as effect measure, and €81 000 (LTx all) and €64 000 (LTx selected) when QALY was used (Figs 4 and 5) . Given a WTP of €70 500, the likelihood of transplantation being cost-effective was 0⋅66 and 0⋅94 based on the cost per life-year gained, and 0⋅23 and 0⋅67 based on cost per QALY gained, for the unselected and selected cohorts respectively ( Table 1, Figs 4 and 5) .
Sensitivity analyses
Figs 2 and 3 show the difference in predicted survival between the scenario analyses. LTx was cost-effective across all scenarios when life-years was used as effect measure, both for the selected and unselected cohorts.
When QALY was used as effect measure, LTx was cost-effective in two of seven scenarios for LTx (all) and in five of seven scenarios for LTx (selected). Further details can be found in Appendix S2, Tables S4-S9 and Figs S1-S12 (supporting information) .
The results of other sensitivity analyses are described in Appendix S2 and Figs S13-S17 (supporting information).
Model validation
The results of the assessment of the face validity, internal validity and external validity of the model can be found in Appendix S3 (supporting information).
Discussion
With increasing pressure on scarce healthcare resources, costs are inevitably a point of discussion when considering whether to implement new interventions 14, 17 . Analyses such as this bring valuable information to the surgeon advising a patient and show that the long overall survival may justify a resource-intensive procedure such as LTx.
No previous study has published results on the cost-effectiveness of LTx for patients with CLM. Clinical outcomes have been reported in 11 studies 8 -10 . The only study 9 that included more than ten patients reported 1-, 3-and 5-year survival rates of 76, 31 and 12 per cent respectively in a series of 25 patients. In that study, published in 1991, the perioperative mortality rate was 30 per cent; however, the study demonstrated that long-term survival after LTx for CLM was possible. The longest post-transplant survival reported so far is 30 years 9,10 . Long-term survival for patients who receive chemotherapy alone has been documented in only 1 per cent of large patient populations 38, 39 . Currently, two patients in the SECA-I trial have lived for 10 years or more, whereas all patients in cohorts from the NORDIC-VII trial died within 6 years (data not shown).
The mean cost of LTx varies between countries 40, 41 . Van der Hilst and colleagues 41 evaluated the factors that influenced cost differences in initial hospital stay between the USA (€142 868) and other Organisation for Economic Co-operation and Development (OECD) countries (€90 516) (both values adjusted for currency and time difference by the present authors). They found that the differences were explained largely by health system characteristics 41 . Given the similar health effects when evaluating LTx in patients with CLM, the ICER might be higher in the USA and lower in other OECD countries 40, 41 . However, other factors such as the unit cost of chemotherapy or different treatment patterns might also influence the ICER 42, 43 . High drug costs in the USA 44 might therefore lead to lower ICERs for LTx in the USA compared with the present findings.
ICERs have rarely been estimated for LTx. Longworth and colleagues 45 estimated the ICER of LTx compared with no LTx in a 27-month perspective for patients with primary biliary cirrhosis (PBC), alcoholic liver disease (ALD) and primary sclerosing cholangitis (PSC) to be €55 964, €92 630 and €40 525 respectively (all values adjusted for time and currency differences). If a 2-year perspective were used in the present model, the ICER would be approximately €360 000 for both cohorts. Åberg and colleagues 46 estimated the 5-year cost per QALY of LTx compared with no LTx in patients with chronic liver disease (CLD) and ALD to be €46 554 and €70 058 respectively (both values adjusted for time and currency differences). If the cost per QALY were estimated using methods similar to those of Åberg and colleagues, LTx for patients with CLM would yield €71 224 per QALY for the unselected cohorts and €63 681 per QALY for the selected cohorts. A comparison with the data of Longworth and co-workers 45 or Åberg et al. 46 is difficult, owing to methodological differences. However, the ICER of LTx for CLM seems to be greater than those for PBC, ALD and PSC as estimated by Longworth et al. 45 , whereas the ICER of LTx for the selected cohorts of patients with CLM seems to be within the range of those for CLD and ALD as estimated by Åberg and colleagues 46 .
A limitation of this study is that the SECA-I trial was small, with no control group, and follow-up was relatively short. It is important to point out that baseline characteristics of the cohorts from the SECA-I trial and the NORDIC-VII trial were similar, but that unobserved selection bias cannot be ruled out 11 . Ideally, model-based cost-effectiveness analyses should use high-quality effect data, preferably based on meta-analyses from several appropriate RCTs 47 . However, under some circumstances (for example, when the effect of a treatment is as large as the effect found for LTx compared with chemotherapy for patients with non-resectable CLM), a decision regarding whether to implement the new treatment should be made before evidence from an RCT is available. It can also be argued that randomizing patients between LTx and chemotherapy is unethical, considering that the SECA-I trial showed that LTx has the potential to increase the 5-year survival rate from 9 to 56 per cent 11, 48 . Model-based analyses can be used as tools explicitly to model the uncertainty of the decision about whether to introduce a new treatment. This was done here by performing several one-way analyses and PSAs. In addition, several scenario analyses were undertaken to test how different methods of extrapolation would alter the results. Therefore, even though model-based cost-effectiveness analyses should ideally be made with evidence from (several) RCTs, models can also be used to give timely information to decision-makers on the expected costs and effects before evidence from an RCT is available, while explicitly showing the uncertainty surrounding the decision. In the future, more analyses performed within the safe framework of decision analytical models should be conducted to estimate the post-transplant survival needed to justify LTx for patients with CLM 49 . Availability of liver allografts, waiting list length and mortality should be included in the models.
Another limitation of this study was that the cost of care was valued using DRGs and tariffs that reflect how care providers are reimbursed and not the actual cost of care. However, as they are estimated to reflect the mean cost of care, they are good sources of valuation in cost-effectiveness analyses 28 -30 . There is a discrepancy between the demand for LTx and the number of liver allografts available for transplantation, and decision-makers should be reluctant to increase the list of transplantable diseases 50 . The limitation of available liver allografts plays a greater role than the costs of LTx in explaining why LTx for CLM has been slow to implement across the world, despite reports of good overall survival 11 . The waiting time and waiting list mortality in Nordic countries are relatively low; in 2016 the median waiting time on the LTx list was 63 days compared with 152 days in the UK, and the number of patients who died on the waiting list relative to the total number of transplantations was 3⋅6 per cent compared with 16 per cent in the UK 51, 52 . From the SECA-I trial 11 and the present study, the estimated 5-year survival rate after LTx was 52 per cent for LTx (all) and 72 per cent for LTx (selected). This is comparable with the survival rate among patients who are currently receiving liver transplants in Nordic countries, which ranges from 87 per cent among patients with PSC to 42 per cent in those with cholangiocarcinoma 12 . LTx should therefore be considered as an option for patients with non-resectable CLM in Norway. LTx for non-resectable CLM might not be a realistic option for the time being in other countries because of longer waiting times and higher waiting list mortality than those in Norway 51, 52 . However, there is currently a focus on how to increase access to liver allografts through procedures such as extended donor criteria, split-liver transplantation and living donor transplantation 50, 53 . If this leads to decreased waiting times and waiting list mortality, LTx for non-resectable CLM might become possible in more countries.
